Ertapenem reduces divalproex sodium concentrations below therapeutic range, increasing risk of breakthrough seizures. Concomitant use is generally not recommended.
Source: NLP:ertapenem
Brand names: Ertapenem Sodium
Route: Intramuscular, Intravenous
Contraindications
4 CONTRAINDICATIONS Ertapenem for injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. Due to the use of lidocaine HCl as a diluent, Ertapenem for injection administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. Known hypersensitivity to product components or anaphylactic reactions to β-lactams. ( 4 ) Due to the use of lidocaine HCl as a diluent, Ertapenem for injection administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk SummaryAvailable data from a small number of postmarketing cases with ertapenem use in pregnancy are insufficient to inform any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies after intravenous administration of ertapenem during the period of organogenesis, there was no evidence of developmental malformations in rats at systemic exposures (AUC) up to approximately 1.2 times the human exposure at the maximum recommended human dose (MRHD) and in mice at doses up to approximately 3 times the MRHD based on body surface area comparison. In pregnant rats administered ertapenem during organogenesis through lactation, fetal toxicity, developmental delays, and impaired reproduction did not occur in first generation offspring at systemic exposures (AUC) approximately 1.2 times the human exposure at the MRHD (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In pregnant rats, intravenous administration of ertapenem dosages of up to 700 mg/kg/day (approximately 1.2 times the MRHD based on AUC) during the period of organogenesis (gestation days [GD] 6-20) revealed no maternal or embryofetal effects. Pregnant mice intravenously administered ertapenem dosages of up to 700 mg/kg/day (approximately 3 times the MRHD based on body surface area comparison) during the period of organogenesis (GD 6-15) showed slight decreases in average fetal weight and an associated decrease in the average number of ossified sacrocaudal vertebrae. There were no maternal effects at any dosage. In a pre-postnatal study in rats, ertapenem administered to preg
5 interactions on record
Ertapenem reduces divalproex sodium concentrations below therapeutic range, increasing risk of breakthrough seizures. Concomitant use is generally not recommended.
Source: NLP:ertapenem
Clinically significant reduction in serum valproic acid concentration reported, potentially resulting in loss of seizure control.
Source: NLP:divalproex sodium er
Carbapenem antibiotic causing clinically significant reduction in serum valproic acid concentration, potentially resulting in loss of seizure control.
Source: NLP:divalproex sodium d/r
Carbapenem antibiotic causing clinically significant reduction in serum valproic acid concentration, potentially resulting in loss of seizure control.
Source: NLP:valproic acid
Probenecid inhibits renal excretion of ertapenem, increasing plasma concentrations. Co-administration is not recommended.
Source: NLP:ertapenem